NIH, CDC, and FDA Parent SBIR (R43/R44) Clinical Trial Optional: PA-27-100

NIH, CDC, and FDA Parent SBIR (R43/R44) Clinical Trial Optional: PA-27-100

The NIH, CDC, and FDA Small Business Innovation Research Parent NOFO (PA-27-100) is a major recurring federal route for small companies to fund research and development that can move toward commercialization in health, diagnostics, life sciences, and other mission-relevant areas. It is explicitly open to Phase I, Phase II, Direct-to-Phase II (NIH), and Fast-Track submissions, and is designed for organizations that can propose and execute a viable scientific development pathway. The NOFO was posted as an active opportunity for 2026–2027 with application cycles and explicit deadlines in mid-September 2026 and again in early 2027.

This page is intended as a practical execution guide. It is not a legal notice summary. For legal language and full instructions, use the full solicitation.

Quick reference: Key details

Why this opportunity is strong for 2026/2027 planning

Most federal R&D funding opportunities in this space are either discipline-narrow grants, university-focused research programs, or one-off mission calls. PA-27-100 is different: it is a broad parent family mechanism. It supports many technical pathways while expecting strong commercialization thinking. In the SBIR system, this matters because your business is evaluated not only on scientific merit but also on whether the project can produce a marketable result, and whether your team can execute from prototype to product development stage.

If your startup is trying to de-risk a new medical device, diagnostic workflow, software intervention, or public-health product, this NOFO gives you a federal route that aligns with staged funding logic. It gives you a clear way to start in Phase I and move to Phase II when milestones are hit, while preserving flexibility for NIH, CDC, or FDA participation depending on your mission fit. For founders and technical operators, this can be more realistic than a single all-in R&D award because it assumes development is iterative and reviewable.

The opportunity is especially relevant for 2026 and 2027 because it is active across these cycles, with at least three official due-date waves in the published schedule. That means there is often enough lead time to watch peer-reviewed priorities, align pilot evidence for the current cycle, and still recover from a missed submission with a future window.

What PA-27-100 actually funds

The NOFO says it supports R43/R44 Small Business Innovation Research (SBIR) grants for U.S. small business concerns conducting R&D to develop commercially usable products or services connected to the missions of participating NIH, CDC, or FDA agencies. The program covers projects ranging from early feasibility work to later-stage commercialization development and is explicitly multi-phase.

What “SBIR parent NOFO” means in practice:

• It is a common solicitation shell used by agencies with specific mission-specific priorities.
• The opportunity includes different award tracks and is connected to institutional and IC-level priorities.
• It is not tied to one narrow scientific disease theme. Instead, it supports many paths as long as the project aligns with participating components.
• It is a startup-stage bridge into commercialization, not just a science publication pipeline.

The most important operational detail: the NOFO is also explicit that small businesses should apply to STTR NOFO when the project depends on formal collaboration with a nonprofit research institution. That is a hard fork in strategy: if your collaboration model is STTR-like and not SBIR-appropriate, you can lose eligibility by choosing the wrong parent family.

Eligibility: who can apply and who cannot

According to the eligibility section, this NOFO is for United States small business concerns only. If your business is not a U.S.-based small concern under SBA rules (as relevant to the program), you should not proceed down this route without legal review. The document also requires:

• A business structure that qualifies as an eligible U.S. SBC.
• Compliance with ownership/affiliation rules (including requirements around U.S. citizen/permanent-resident ownership control in most standard paths).
• A clear distinction between standard SBC ownership and venture-capital-heavy structures, which can involve additional certification requirements.

The NOFO also makes clear that foreign organizations and non-U.S. components are not eligible as applying entities. Unfunded collaborations may be possible in limited forms, but funded foreign subcontracting is generally restricted under the active policy in this solicitation context.

For the PI/PD side:

• The Program Director/Principal Investigator must be properly registered and able to submit with the host organization.
• PD(s)/PI(s) need an active eRA Commons account and valid ORCID association in profile.
• The organization’s required registrations (for example SAM/eRA Commons/Grants.gov prerequisites) must be complete before submission.

If you are planning an SBIR application strategy, treat registration readiness as part of project execution, not admin overhead. Registration delays are a frequent cause of late or rejected submissions.

Application tracks, phases, and what they imply

The NOFO supports the following submission modes:

Phase I

This is feasibility R&D. Typical constraints in federal SBIR frameworks apply: shorter project time and a sharper proof-of-concept scope.

Phase II

This is the later-stage expansion phase with larger implementation scope and stronger commercialization planning expectations.

Direct to Phase II (NIH only)

The NOFO states NIH can accept Direct-to-Phase-II applications for projects already showing technical and scientific merit and feasibility, even if not funded through Phase I/II SBIR/STTR under this same mechanism.

Fast-Track

Allows Phase I and Phase II submission in one package, reducing some timing uncertainty and potentially shortening the handoff between phases.

Practical implication

For founders, the right choice matters operationally:

• If your technical package is narrow and needs quick validation, Phase I is usually right.
• If your product validation is already mature with defensible preclinical/clinical or technical data, Fast-Track or Direct-to-Phase II may be more efficient.
• If your goal is near-term commercialization and you already have strong pilots, you should still treat PI capability and commercialization plan as if you are applying to competitive review at the top end.

Budget expectations and award scale

Budget rules are not a single fixed amount across all tracks. The NOFO includes a table with component-level budget guidance, and values vary by participating NIH institute/center and phase. Reported examples in the solicitation include

• NIH NCI Phase I around $700,000 with Phase II around $2.5M,
• NHLBI/Oncological and several other institutes with Phase I around $400,000–$700,000 and Phase II around $2.5M–$3.0M,
• Several participating components with SBA guideline caps instead of fixed amounts.

You should treat these as guidance and caps rather than a guaranteed grant amount. The project should present a budget that is technically justified and realistic for the proposed scope.

Common misconception: budget size does not by itself determine competitiveness. A tighter, more executable proposal can outperform a larger but vague budget package.

Official timeline for 2026–2027

The NOFO’s application table lists three key cycles in the cycle window:

• September 5, 2026
• January 5, 2027
• April 5, 2027

All cycles are local-time 5:00 PM deadlines for applicant organizations. The NOFO notes no late applications are accepted, and if a due date lands on weekend/holiday, the next business day extension rule applies.

Expiration is listed as April 6, 2027.

Because these are recurring standard NIH dates, teams can often use this as a planning framework:

1. Target one internal cutoff one to two weeks before the NIH/Grants.gov date.
2. Leave two additional weeks for signature and compliance checks.
3. Reserve final day for error correction and failed uploads if a compliance issue is detected.

Given the NOFO states “no late applications,” this timeline is strict.

Submission workflow, required pieces, and common compliance traps

Applications must go through the SBIR/STTR(B) process in Grants.gov/eRA Commons ecosystem and follow NIH “How to Apply” instructions with NOFO-specific supplements. In practical terms:

Core submission points

• Use approved systems-to-system or ASSIST/Grants.gov Workspace package.
• Ensure the application package corresponds to this specific opportunity and activity type.
• Confirm that all required forms and attachments are present.
• Verify eRA Commons identity of PD/PI roles before final submission.

Required registrations

The NOFO emphasizes that all registrations are required before submission:

• SAM registration
• eRA Commons setup
• Grants.gov registration/account state

These can take weeks. Build them into your internal schedule early. Do not assume they are instant.

Required/conditional uploads (depending on project)

At minimum, your package must satisfy baseline SF424(R&R) requirements, including the required research plan and all compliance fields. Additional attachments include:

• SBIR Certification attachment for certain venture-capital-multi-owned firms (if applicable), with exact file naming requirements.
• Regulatory Plan attachment when your proposal includes a clinical trial.
• Research plan sections with compliance and scope-appropriate limits.

Important trap: the NOFO explicitly distinguishes that commercial plans are not allowed for Phase I in some contexts, and clinical-trial attachments are required when applicable. If you submit wrong attachments or wrong-named files, your application can be delayed or rejected for compliance reasons.

Common application mistakes to avoid

• Missing correct registration state before final submission.
• Using the wrong opportunity family (SBIR vs STTR).
• Submitting similar/overlapping applications across windows that violate overlap rules.
• Uploading incorrect file names for mandatory attachments.
• Proposing a project with over-ambitious commercialization statements for Phase I.
• Weak registration and credentials for PD/PI in eRA Commons.

These are not “nice-to-have” issues. They are failure points.

Review process and what reviewers prioritize

The NOFO review criteria use NIH peer-review logic with business-specific emphasis for SBIR. In short, scoring includes:

• Significance: clear unmet need and project value.
• Investigator/Team strength: ability of PI and team to execute technical and commercialization components.
• Innovation and approach for the science and proposed development path.
• Commercialization (especially Phase II/Fast-Track): target customers, barriers to commercialization, reimbursement pathways, adoption and revenue path.
• Budget and period of support alignment with work plan.

In SBIR terms, “nice science” is not enough if commercial pathway assumptions are weak. Reviewers expect you to justify who will buy, test, adopt, or scale your output, and how resources align.

Second-stage review generally includes council/advisory review and then funding-level decisions that incorporate merit, priorities, available budget, and security/compliance factors.

Fit and preparation strategy for this specific cycle

If your company is not sure whether to apply, use this decision rubric:

1. Can you define a clear productized output? If your proposal is just a research question with no development path, this route will be weak.
2. Is the SBC the driver, not just an administrative front? SBIR awards are to the concern, but scientific execution must be by the company.
3. Can you show commercialization readiness in a Phase II/Fast-Track? Even early projects should state where commercialization risk is still being reduced.
4. Can you support NIH/CDC/FDA mission relevance? General commercialization without mission tie-in is often insufficient.
5. Can you satisfy required compliance steps by deadline? If not, you need to build registration and identity work before strategy work.

A good preparatory sequence:

• Map your technical route to one of the three SBIR tracks (Phase I, Direct-to-Phase II, Fast-Track).
• Choose one main and one backup institute/component fit (NIH/CDC/FDA relevant office).
• Draft a concise commercialization plan section with customer logic, timeline, and go-to-market assumptions.
• Pre-build all required accounts and have ORCID linked to PI profiles.
• Finalize a compliance package (registration, file names, and attachment rules) before writing final results.

Official links and documents

Primary source document:

• PA-27-100 full solicitation (official): https://files.simpler.grants.gov/opportunities/d1ba49e5-3684-4420-849a-ab2330ec493e/attachments/e153af86-fe8f-4171-9b7e-d840f64f37b2/PA-27-100-Full-Announcement.html

Related companion notices and context:

• PA-27-101 (NIH SBIR Phase II bridge): https://files.simpler.grants.gov/opportunities/a44b38f2-6d15-4b5b-b1df-788a730bb203/attachments/ade120a7-9eae-4ae7-9ef3-e6f1d5d9ff19/PA-27-101-Full-Announcement.html
• PA-27-102 (NIH/CDC/FDA STTR): https://files.simpler.grants.gov/opportunities/ee37f2de-b959-4b45-86a9-43d06c944f24/attachments/f1943a30-a460-40f4-91a8-49ac401bf1f0/PA-27-102-Full-Announcement.html
• NIH parent announcements list (includes current dates): https://grants.nih.gov/funding/explore-nih-opportunities/parent-announcements
• NIH Application Guide: https://grants.nih.gov/grants/how-to-apply.html

FAQ

Is this opportunity currently only for Phase I?

No. It supports multiple tracks, including Phase I, Phase II, Fast-Track, and Direct-to-Phase II for NIH.

Is there a guaranteed fixed funding amount?

No. Amounts vary by component and phase, and the solicitation provides caps and ranges rather than a single fixed amount.

Can foreign entities apply as lead applicants?

No. The NOFO does not allow funded foreign organizations as applying entities. Some non-funded international collaboration models may still be possible, but funded foreign subawards are restricted.

Can the PI handle multiple competing applications in the same cycle?

The NOFO has overlap rules that can restrict highly similar applications. You should review overlap policy carefully before planning multiple submissions.

Where should teams track submission correctness?

Use Grants.gov and eRA Commons together; the source systems are part of the compliance gate.

Bottom line for 2026/2027 planning

If your company has a valid commercialization thesis, technical milestones, and U.S. small-business eligibility, PA-27-100 remains one of the most flexible federal routes for health-adjacent deep-tech development in 2026–2027. The strategy is straightforward but strict: build a submission with a defensible market pathway, satisfy mandatory compliance prerequisites early, and treat the deadline windows as hard gates.

The opportunity rewards teams that think like companies, not only scientists: clear product need, execution ownership in the SBC, and a realistic path from research output to adoption.